Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial Evommune, Inc.
(NYSE:EVMN) stock is trading lower on Monday after its investigational therapy EVO756 failed to meet the primary endpoint in a mid-stage study in patients with chronic spontaneous urticaria (CSU).
The update prompted the clinical-stage biotechnology company to discontinue development of the drug candidate for the indication.
The study enrolled 160 patients with antihistamine-refractory moderate-to-severe CSU, an inflammatory condition causing recurring, itchy hives or swelling (angioedema) that lasts for more than 6 weeks without an obvious external trigger.
Evommune said the trial did not achieve its primary endpoint, which measured the mean change from baseline in the Urticaria Activity Score over seven days (UAS7) at Week 12.
